whyframestudio/iStock via Getty Images I have been a follower and a fan of Ionis (NASDAQ: IONS ) since 04/2018’s Ionis article "Ionis: Cash, Catalysts And More". In 03/2022’s "Ionis: At A Show-Me Crossroads" (" Crossroads "), I reflected on why Ionis had fallen back from its glory days when it had showed promise of trading up to $100 and discussed its then forward prospects . In this article, I update Crossroads based on latest available Ionis developments, including its Q3,2022 Earnings call (the " Call ") and CEO Monia’s presentation at the 01/2023 41st Annual J.P. Morgan Healthcare Conference (the " Presentation "). Ionis’ ALS SOD1 PDUFA is fast approaching. Ionis has long generated healthy royalty revenues from its SPINRAZA (nusinersen) deal with Biogen ( BIIB ). They totaled ~$268 million in 2021 compared to ~$287 million in 2020. Its Q3, 2022 10-Q reported its product revenues from Spinraza, and lesser revenues from WAYLIVRA and TEGSEDI as set out below: seekingalpha.com This off kilter tri-legged stool of product revenues, with SPINRAZA as the workhorse and TEGSEDI and WAYLIVRA as the distant also-rans, has been the case for several years. As described in Crossroads, Ionis has recently been on something […]
K&X Design and Investment Technology, LLC
Invest The Invisible Impact
K&X Design and Investment Technology, LLC
Invest The Invisible Impact
